Literature DB >> 3415281

Cutaneous hypoxia in patients with systemic sclerosis (scleroderma).

J L Silverstein1, V D Steen, T A Medsger, V Falanga.   

Abstract

Measurement of transcutaneous oxygen pressure (TCPO2) is an established and noninvasive way of assessing cutaneous hypoxia. Since the degree of oxygenation modulates fibroblast growth and synthesis, we investigated the presence of cutaneous hypoxia in patients with systemic sclerosis (SS). We measured TCPO2 of the involved skin of the dorsal aspect of the forearm in 33 patients with SS and 16 control individuals (normal subjects and patients with Raynaud's disease). The degree of forearm skin thickness was assessed clinically as mild, moderate, or severe. The TCPO2 measurements were obtained at a sensor temperature of 44 degrees C, which causes maximal vasodilation and eliminates the variables associated with vascular tone. Measurements were recorded while patients were breathing room air or 31% oxygen delivered by a Ventimask system (Baxter Healthcare, Ocala, Fla). We also measured the TCPO2 of the medial aspect of the arm when this site was uninvolved. We found that sclerodermatous skin is hypoxic when compared with the uninvolved skin of patients with SS or control individuals. The TCPO2 values were indirectly related to skin thickness; thus, patients whose skin was severely thickened had the lowest TCPO2 values. There was no correlation of TCPO2 values with pulmonary function tests or arterial oxygen pressure. The TCPO2 levels of patients with Raynaud's disease did not differ from other control individuals. The administration of oxygen increased TCPO2 readings in patients with SS to normal values. We conclude that the thickened skin of patients with SS is hypoxic and suggest that TCPO2 measurements may be helpful in objectively assessing the degree of skin thickness. The hypoxia demonstrated in SS skin may play a role in the modulation of dermal fibroblast proliferation and synthetic activity.

Entities:  

Mesh:

Year:  1988        PMID: 3415281

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  9 in total

Review 1.  Raynaud's phenomenon: its relevance to scleroderma.

Authors:  J J Belch
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

Review 2.  Scleroderma therapy: clinical overview of current trends and future perspective.

Authors:  Afsha A Topal; Rachita S Dhurat
Journal:  Rheumatol Int       Date:  2012-08-03       Impact factor: 2.631

3.  Transcutaneous oxygen pressure in systemic sclerosis: evaluation at different sensor temperatures and relationship to skin perfusion.

Authors:  G Valentini; G Leonardo; D A Moles; M R Apaia; R Maselli; G Tirri; R Del Guercio
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

4.  Enhanced angiogenic potency of monocytic endothelial progenitor cells in patients with systemic sclerosis.

Authors:  Yukie Yamaguchi; Yuka Okazaki; Noriyuki Seta; Takashi Satoh; Kazuo Takahashi; Zenro Ikezawa; Masataka Kuwana
Journal:  Arthritis Res Ther       Date:  2010-11-04       Impact factor: 5.156

5.  A system out of breath: how hypoxia possibly contributes to the pathogenesis of systemic sclerosis.

Authors:  T W van Hal; L van Bon; T R D J Radstake
Journal:  Int J Rheumatol       Date:  2011-11-20

6.  Elevated matrix metalloproteinase-9 in patients with systemic sclerosis.

Authors:  Wan-Uk Kim; So-Youn Min; Mi-La Cho; Kyung-Hee Hong; Yong-Joo Shin; Sung-Hwan Park; Chul-Soo Cho
Journal:  Arthritis Res Ther       Date:  2004-11-10       Impact factor: 5.156

7.  Postocclusive Hyperemia Measured with Laser Doppler Flowmetry and Transcutaneous Oxygen Tension in the Diagnosis of Primary Raynaud's Phenomenon: A Prospective, Controlled Study.

Authors:  Paweł Maga; Brandon Michael Henry; Elizabeth K Kmiotek; Iwona Gregorczyk-Maga; Paweł Kaczmarczyk; Krzysztof A Tomaszewski; Rafał Niżankowski
Journal:  Biomed Res Int       Date:  2016-12-22       Impact factor: 3.411

Review 8.  Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis.

Authors:  Christian Beyer; Georg Schett; Steffen Gay; Oliver Distler; Jörg H W Distler
Journal:  Arthritis Res Ther       Date:  2009-04-21       Impact factor: 5.156

Review 9.  Engineering Advanced In Vitro Models of Systemic Sclerosis for Drug Discovery and Development.

Authors:  Andrea De Pieri; Benjamin D Korman; Astrid Jüngel; Karin Wuertz-Kozak
Journal:  Adv Biol (Weinh)       Date:  2021-02-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.